Teniposide Suppliers & Bulk Manufacturers
Available Forms: Injection (IV)
Available Strengths: 50 mg/5 mL (10 mg/mL vial)
Reference Brands: Vumon® (EU & US)
Category:
Oncology Cancer Care
Teniposide is a topoisomerase II inhibitor used in oncology, primarily for treating acute lymphoblastic leukemia (ALL) in pediatric patients. Marketed under the brand name Vumon®, it is available in 50 mg/5 mL (10 mg/mL) IV vials in both the US and EU. Teniposide is a critical component in combination chemotherapy protocols and is supplied under GMP-compliant manufacturing. Ideal for pharma B2B partners, Teniposide supports trusted oncology supply chains across regulated markets.
Teniposide is available in Injection (IV)
and strengths such as 50 mg/5 mL (10 mg/mL vial).
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Teniposide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Teniposide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Teniposide Injection is a potent chemotherapeutic agent used in the treatment of acute lymphoblastic leukemia (ALL), especially in pediatric patients with relapsed or refractory disease. Classified as a topoisomerase II inhibitor, Teniposide disrupts DNA replication and cell division, making it effective in oncology protocols. It is commercially available in the US and EU under the brand name Vumon®, typically in 50 mg/5 mL (10 mg/mL) injectable vials. Teniposide is manufactured under strict GMP standards, making it ideal for B2B pharmaceutical distributors, hospital tenders, and global supply chains seeking reliable oncology solutions in regulated markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing